Medtronic Stock News

Long-term investors shouldn't overlook this top pharma stock and top medical device maker. AbbVie is seeing impressive growth from both its immunology portfolio and neuroscience products.

NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will host a business update call on Wednesday, November 12th at 8:0...

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW, and IBM have delivered strong double-digit returns this year. Dividend growth for the Aristocrats in 2025 averages 5.27%, with most constituents raising payouts, though growth may not exceed 2024...

Symplicity blood pressure procedure is now covered for qualifying Medicare patients GALWAY, Ireland , Oct. 28, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal denervation, applicable to the Symplicity Spyral™ rena...

Intuitive Surgical is the market leader in robotic surgery systems, and has ample growth prospects. Medtronic has a diversified business, some growth opportunities, and a fantastic dividend record.

Every large company has to deal with both industry conditions and the efficiency of their own business. Pfizer is making the changes needed to deal with the world around it and handle normal issues in the drug sector.

Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplicity™ blood pressure procedure in patients prescribed antihypertensive medications GALWAY, Ireland , Oct. 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology...

Medtronic's shares have sharply rallied over the last six months. The medtech giant's growth catalysts include a best-in-class product (Affera) in a fast-growing $11 billion space and a massive opportunity in the underpenetrated urge urinary incontinence market. Medtronic possesses an A S&P credit rating with a stable outlook.